111 related articles for article (PubMed ID: 17474454)
1. [Molecular target therapy--gemtuzumab ozogamicin].
Usui N
Nihon Rinsho; 2007 Jan; 65 Suppl 1():494-8. PubMed ID: 17474454
[No Abstract] [Full Text] [Related]
2. Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Ronconi S; Visani G; Baccarani M
Haematologica; 2003 Dec; 88(12):ECR37. PubMed ID: 14688010
[No Abstract] [Full Text] [Related]
3. [Gemtuzumab ozogamicin as monotherapy and combination therapy for acute myelogenous leukemia].
Usui N
Rinsho Ketsueki; 2007 Jun; 48(6):458-67. PubMed ID: 17633093
[No Abstract] [Full Text] [Related]
4. Gemtuzumab ozogamicin: is there room for salvage?
Clarke WT; Marks PW
Blood; 2010 Oct; 116(14):2618-9. PubMed ID: 20930085
[No Abstract] [Full Text] [Related]
5. Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?
O'Hear C; Rubnitz JE
Expert Rev Hematol; 2014 Aug; 7(4):427-9. PubMed ID: 24871925
[TBL] [Abstract][Full Text] [Related]
6. Remission induction in a Jehovah's witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin.
Bareford D; Odeh B; Narayanan S; Wiltshire S
Transfus Med; 2005 Oct; 15(5):445-8. PubMed ID: 16202062
[TBL] [Abstract][Full Text] [Related]
7. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
8. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
9. Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study.
Poloni A; Capelli D; Trappolini S; Costantini B; Montanari M; Gini G; Scortechini I; Mancini G; Discepoli G; Leoni P; Olivieri A
Br J Haematol; 2010 Jul; 150(1):119-21. PubMed ID: 20377587
[No Abstract] [Full Text] [Related]
10. Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia.
El Kinge AR; Hatoum HA; Mahfouz RA; Otrock ZK; Jabbour E; Kantarjian H; Bazarbachi A
Leuk Res; 2009 Apr; 33(4):565-6. PubMed ID: 18571231
[No Abstract] [Full Text] [Related]
11. Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia.
Cascavilla N; D'Arena G; Greco MM; Melillo L; Merla E; Carella AM
Br J Haematol; 2008 Sep; 142(5):852-3. PubMed ID: 18510691
[No Abstract] [Full Text] [Related]
12. Sensorimotor peripheral neuropathy in an elderly AML patient in complete remission while receiving gemtuzumab ozogamicin as maintenance therapy.
Romani C; Murru R; Adamo F; Di Tucci A; Sabiu D; Casula P; Angelucci E
Ann Hematol; 2006 Jun; 85(6):411-2. PubMed ID: 16538500
[No Abstract] [Full Text] [Related]
13. Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.
Ichikawa M; Hangaishi A; Nannya Y; Kurokawa M
Int J Hematol; 2010 Nov; 92(4):673-4. PubMed ID: 20978876
[No Abstract] [Full Text] [Related]
14. [Revision of treatment with gemtuzumab ozogamicin using 3 clinical case studies].
Fernández Cañabate E; Longoni Merino M; Estany Raluy C; Pla Poblador R
Farm Hosp; 2008; 32(6):360-2. PubMed ID: 19232223
[No Abstract] [Full Text] [Related]
15. [Gemtuzumab ozogamicin and targeted cancer therapy].
Imaizumi M
Nihon Yakurigaku Zasshi; 2004 Jul; 124(1):25-9. PubMed ID: 15226619
[TBL] [Abstract][Full Text] [Related]
16. [Gemtuzumab ozogamicin combined chemotherapy for elderly patients with acute myeloid leukemia].
Ito Y
Rinsho Ketsueki; 2014 May; 55(5):508-17. PubMed ID: 24881915
[No Abstract] [Full Text] [Related]
17. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Stasi R; Evangelista ML; Buccisano F; Venditti A; Amadori S
Cancer Treat Rev; 2008 Feb; 34(1):49-60. PubMed ID: 17942233
[TBL] [Abstract][Full Text] [Related]
18. Antibody therapy for acute myeloid leukemia.
Mulford D
Semin Hematol; 2008 Apr; 45(2):104-9. PubMed ID: 18381105
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.
Mele A; Sparaventi G; Guiducci B; Nicolini G; d'Adamo F; Leopardi G; Delfini C; Piccaluga P; Visani G
Haematologica; 2004 Jun; 89(6 Suppl):ECR18. PubMed ID: 15194554
[No Abstract] [Full Text] [Related]
[Next] [New Search]
